Hepatitis B is a serious and debilitating human disease caused by hepatitis B virus (HBV) infection. HBV infection is species-specific with a narrow host range. Chimpanzees may be considered the most effective host for the study of HBV infection when considering HBV infection rate and maintenance. However, the study of HBV in chimpanzees is heavily limited due to multiple ethical considerations. Tree shrews may serve as an alternative animal model for HBV infection, yet several shortcomings including the low infection rate, infection maintenance time, stability and repeatability limit the utility of Tree Shrews for HBV research. Due to these limitation associated with non-human primate models for the study of HBV mice with a uniform genetic background are often considered the best choice for HBV infection studies.
PackGene’s AAV-HBV carries a 1.3×HBV full-length genome, and a mouse model of persistent HBV infection can be prepared by one-time tail vein injection of AAV-HBV. This approach has several advantages including simple preparation, high success rate, uniformity, stability, a well-characterized dose-effect relationship, and a wide application range. Furthermore, the HBV-AAV mouse model has been validated and used across a wide range of HBV drug evaluations and vaccine screenings.
In addition to the advantages listed above, use of the AAV-HBV mouse model can greatly shorten preparation time for in vivo hepatitis B infection therapy research and development. This, when paired with the relatively low cost of the model, can help to accelerate the development of hepatitis B drug research and treatment programs. PackGene’s AAV-HBV viral vectors provide long terms stable expression of hepatitis B antigen for the fast and safe modeling of HBV.
Compared with Lentivirus and Adenovirus, rAAV shows outstanding safety advantages including an low probability of genome integration, low immunogenicity, and high experimental operation safety.
Over the past 20 years, rAAV has been commonly used as a tool for efficient and long-term gene expression in basic research and clinical gene therapy. For example, rAAV induced transgene expression in non-human primate muscle tissue can last for more than 10 years.
The capsid proteins of different AAV serotypes recognize different receptors on the cell surface, cell infection efficiency varies across tissues, indicating organ targeting specificity. AAV8 is frequently used in liver research and is therefore the serotype of choice for generation of the AAV-HBV mouse model.
Low Empty Shell
AAV-HBV TEM detects empty shell rate is below 30%
Low endotoxin levels with <10EU/ml – suitable for animal experiments.
AAV-HBV Mycoplasma Test Negative
High Purity Titer
≥1E+13GC/ml for AAV8-based qPCR genome copies/ml
Complete Quality Inspection Reports Are Provided
|Genotype||HBV-D genotype, AYW genotype||HBV-C genotype, ADR genotype||HBV-C2, replication defective||HBV-B genotype, ADW genotype|
|Vector||HBV-D-AYW 1.3||HBV-C-ADR 1.3||HBV-C-YMHA-1.3||HBV-B-Adw 1.3|
|Remark||Epidemic worldwide and in part of China||Mainly epidemic in Asia and China with strong pathogenicity||Epidemic in Asia||Mainly epidemic in Asia and China with less pathogenicity compared with HBV-C type|
50ul and 100ul specification are available.
In 1994, the safety of rAAV as a gene therapy vector was recognized by the FDA. AAV are classified as biological safety is Grade 1 (BSL-1), which is the same as that of plasmid DNA. It is nevertheless recommended to adhere to BSL-2 laboratory precautions with a ClassⅡ biological safety cabinet for use.
Store the virus at -80°C and place it on ice during operation.
Calculate your expected usage in advance and PackGene will aliquot your virus according to your pre-determined requirements. This can help avoid unnecessary thawing and re-freezing after receiving your AAVs since freeze thaw cycles influence virus viability. If aliquoting is required, it is recommended to use PCR tubes with siliconized inner walls, or special virus preservation tubes with low protein binding rates.
Thaw your virus aliquots in an ice bath immediately before use.
Dilute with PBS or PBS / 0.001% F-68 if needed.
Individual differences between operators and regional mouse available may result in inter-lab differences in AAV-HBV transgene expression. We therefore strongly recommended that a gradient of 3 to 4 AAV-HBV volumes injection be tested before formal experiments are carried out. For example, we may recommend testing a total of three serial dilutions: 1E+11GC; 2E+11GC; 3E+11GC.
Off the Shelf AAV Products
We offer a wide catalogue of pre-made AAVs for a multitude of research needs.
AAV Packaging Services
Ranging from pilot to industrial-scale AAV packaging for both in vitro and in vivo studies.
AAV Analytical Services
We are one of the few vendors that can do ALL in-house.